专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2012107706A8 PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE 审中-公开
标题翻译：双酚钠金属盐及其使用
公开(公告)号：WO2012107706A8
公开(公告)日：2013-09-19
申请号：PCT/GB2011001221
申请日：2011-08-15
申请人： WISTA LAB LTD , MARSHALL COLIN , CLUNAS SCOTT , STOREY JOHN MERVYN DAVID , SINCLAIR JAMES PETER , BADDELEY THOMAS CRAVEN , ISHAQ AHTSHAM , SIMPSON MICHAEL , WILLIAMSON CRAIG , WOOD BARRY ALAN , WISCHIK CLAUDE MICHEL , HARRINGTON CHARLES ROBERT , RICKARD JANET ELIZABETH , HORSLEY DAVID , LOH YIN SZE , KHAN KARRAR AHMAD
发明人： MARSHALL COLIN , CLUNAS SCOTT , STOREY JOHN MERVYN DAVID , SINCLAIR JAMES PETER , BADDELEY THOMAS CRAVEN , ISHAQ AHTSHAM , SIMPSON MICHAEL , WILLIAMSON CRAIG , WOOD BARRY ALAN , WISCHIK CLAUDE MICHEL , HARRINGTON CHARLES ROBERT , RICKARD JANET ELIZABETH , HORSLEY DAVID , LOH YIN SZE , KHAN KARRAR AHMAD
IPC分类号： C07D279/20 , A61K31/5415 , A61P25/00
CPC分类号： A61K31/5415 , A61K9/0053 , A61K9/2095 , A61K9/2893 , A61L2/0052 , C07C303/32 , C07C309/04 , C07C309/05 , C07C309/30 , C07C309/35 , C07D279/20
摘要： The invention relates to compounds of general formula (I): wherein: each of R1 and R9 is independently selected from: -H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: -H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: -H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; and wherein: each of RA and RB is independently selected from: C1-4alkyl, halogenated C1-4alkyl, and C6-10aryl; or RA and RB are linked to form a group selected from: C1-6 alkylene and C6-10 arylene; and pharmaceutically acceptable salts thereof, which are useful in the treatment of, for example, Alzheimer's disease. In other aspects the invention also relates to novel formulations of 3,7-diamino-10H-phenothiazinium salts.
摘要翻译：本发明涉及通式（I）的化合物：其中：R 1和R 9各自独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; R 3NA和R 3NB中的每一个独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; R7NA和R7NB中的每一个独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; 并且其中：RA和RB各自独立地选自：C 1-4烷基，卤代C 1-4烷基和C 6-10芳基; 或RA和RB连接形成选自以下的基团：C 1-6亚烷基和C 6-10亚芳基; 和其药学上可接受的盐，其可用于治疗例如阿尔茨海默氏病。在其它方面，本发明还涉及3,7-二氨基-10H-吩噻嗪鎓盐的新配方。

2. 发明申请

WO2012107706A1 PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE 审中-公开
标题翻译：双酚钠金属盐及其使用
公开(公告)号：WO2012107706A1
公开(公告)日：2012-08-16
申请号：PCT/GB2011/001221
申请日：2011-08-15
申请人： WISTA LABORATORIES LTD. , MARSHALL, Colin , CLUNAS, Scott , STOREY, John, Mervyn, David , SINCLAIR, James, Peter , BADDELEY, Thomas, Craven , ISHAQ, Ahtsham , SIMPSON, Michael , WILLIAMSON, Craig , WOOD, Barry, Alan , WISCHIK, Claude, Michel , HARRINGTON, Charles, Robert , RICKARD, Janet, Elizabeth , HORSLEY, David , LOH, Yin, Sze , KHAN, Karrar, Ahmad
发明人： MARSHALL, Colin , CLUNAS, Scott , STOREY, John, Mervyn, David , SINCLAIR, James, Peter , BADDELEY, Thomas, Craven , ISHAQ, Ahtsham , SIMPSON, Michael , WILLIAMSON, Craig , WOOD, Barry, Alan , WISCHIK, Claude, Michel , HARRINGTON, Charles, Robert , RICKARD, Janet, Elizabeth , HORSLEY, David , LOH, Yin, Sze , KHAN, Karrar, Ahmad
IPC分类号： C07D279/20 , A61K31/5415 , A61P25/00
CPC分类号： A61K31/5415 , A61K9/0053 , A61K9/2095 , A61K9/2893 , A61L2/0052 , C07C303/32 , C07C309/04 , C07C309/05 , C07C309/30 , C07C309/35 , C07D279/20 , Y02A50/393 , Y02A50/411
摘要： The invention relates to compounds of general formula (I): wherein: each of R 1 and R 9 is independently selected from: -H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R 3NA and R 3NB is independently selected from: -H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R7NA and R7NB is independently selected from: -H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; and wherein: each of R A and R B is independently selected from: C 1-4 alkyl, halogenated C 1-4 alkyl, and C 6-10 aryl; or R A and R B are linked to form a group selected from: C 1-6 alkylene and C 6-10 arylene; and pharmaceutically acceptable salts thereof, which are useful in the treatment of, for example, Alzheimer's disease. In other aspects the invention also relates to novel formulations of 3,7-diamino-10H-phenothiazinium salts.
摘要翻译：本发明涉及通式（I）的化合物：其中：R 1和R 9各自独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; R 3NA和R 3NB中的每一个独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; R7NA和R7NB中的每一个独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; 并且其中：RA和RB各自独立地选自：C 1-4烷基，卤代C 1-4烷基和C 6-10芳基; 或RA和RB连接形成选自以下的基团：C 1-6亚烷基和C 6-10亚芳基; 和其药学上可接受的盐，其可用于治疗例如阿尔茨海默氏病。在其它方面，本发明还涉及3,7-二氨基-10H-吩噻嗪鎓盐的新配方。

3. 发明申请

WO2007110630A1 THIONINIUM COMPOUNDS AND THEIR USE 审中-公开
标题翻译：硫化钠化合物及其用途
公开(公告)号：WO2007110630A1
公开(公告)日：2007-10-04
申请号：PCT/GB2007/001107
申请日：2007-03-28
申请人： WISTA LABORATORIES LTD. , WISCHIK, Claude, Michel , RICKARD, Janet, Elizabeth , HARRINGTON, Charles, Robert , HORSLEY, David , STOREY, John, Mervyn, David , MARSHALL, Colin , SINCLAIR, James, Peter
发明人： WISCHIK, Claude, Michel , RICKARD, Janet, Elizabeth , HARRINGTON, Charles, Robert , HORSLEY, David , STOREY, John, Mervyn, David , MARSHALL, Colin , SINCLAIR, James, Peter
IPC分类号： A61P25/28 , A61K31/5415
CPC分类号： A61K31/5415
摘要： This invention pertains generally to processes, uses, methods and materials utilising particular diaminophenothiazinium compounds, specifically, ETC, DEMTC, DMETC, DEETC, MTZ, ETZ, MTI, MTI.HI, ETI, ETI.HI, MTN, and ETN. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease.
摘要翻译：本发明一般涉及利用特定二氨基吩噻嗪鎓化合物，特别是ETC，DEMTC，DMETC，DEETC，MTZ，ETZ，MTI，MTI.HI，ETI，ETI.HI，MTN和ETN的方法，用途，方法和材料。这些化合物可用作药物，例如治疗tau蛋白病，例如阿尔茨海默氏病。

4. 发明申请

WO2007110629A1 INHIBITORS OF PROTEIN AGGREGATION 审中-公开
标题翻译：蛋白质聚集抑制剂
公开(公告)号：WO2007110629A1
公开(公告)日：2007-10-04
申请号：PCT/GB2007/001105
申请日：2007-03-28
申请人： WISTA LABORATORIES LTD , WISCHIK, Claude, Michel , RICKARD, Janet, Elizabeth , HARRINGTON, Charles, Robert , HORSLEY, David
发明人： WISCHIK, Claude, Michel , RICKARD, Janet, Elizabeth , HARRINGTON, Charles, Robert , HORSLEY, David
IPC分类号： A61K31/00 , A61K31/5415 , A61P25/28 , A61P25/16 , A61K49/00
CPC分类号： C07D279/20 , A61K31/5415 , A61K49/0002 , A61K49/003 , A61K51/0465 , G01N33/6896 , G01N2800/2835 , Y02A50/393 , Y02A50/411
摘要： The invention relates generally to the use of diaminophenothiazine compounds to inhibit or reverse the aggregation of synuclein, and for their use in the manufacture of medicaments for this purpose (e.g. for the treatment of Parkinson's Disease). Also provided are related methods of detecting or labelling of aggregated synuclein.
摘要翻译：本发明一般涉及二氨基吩噻嗪类化合物用于抑制或逆转突触核蛋白的聚集，并且用于制备用于此目的的药物（例如用于治疗帕金森病）。还提供了检测或标记聚集的突触核蛋白的相关方法。

5. 发明申请

WO02059150A3 MATERIALS AND METHODS RELATING TO PROTEIN AGGREGATION IN NEURODEGENERATIVE DISEASE 审中-公开
标题翻译：相关蛋白质聚集在神经病变疾病中的材料与方法
公开(公告)号：WO02059150A3
公开(公告)日：2002-12-05
申请号：PCT/GB0200005
申请日：2002-01-02
申请人： UNIV ABERDEEN , WISCHIK CLAUDE MICHEL , RICKARD JANET ELIZABETH , HORSLEY DAVID , HARRINGTON CHARLES ROBERT , THEURING FRANZ , STAMER KARSTEN , ZABKE CLAUDIA
发明人： WISCHIK CLAUDE MICHEL , RICKARD JANET ELIZABETH , HORSLEY DAVID , HARRINGTON CHARLES ROBERT , THEURING FRANZ , STAMER KARSTEN , ZABKE CLAUDIA
IPC分类号： A01K67/027 , A61K45/00 , A61P25/28 , A61P43/00 , C07K14/47 , C07K19/00 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/85 , C12P21/02 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/68 , C12N15/11 , C12N15/62
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/20 , A01K2227/105 , A01K2267/0312 , A01K2267/0318 , C07K14/4711 , C07K2319/00 , G01N33/6896 , G01N2500/00
摘要： Disclosed are methods of inducing or modelling the pathological state of an aggregating disease protein (ADP - e.g. tau protein) which is associated with a disease state in which the ADP aggregates pathologically (e.g. Alzheimer's disease) through an induced conformational polymerisation interaction, the method being characterised by the step of providing a membrane-localisable fusion protein comprising (i) an aggregating portion, which is derived from the ADP, or from a protein which initiates pathological aggregation of the ADP, (ii) a heterologous membrane-localising portion. Membrane-localisation of the ADP-based fusion protein is believed to cause the high-affinity capture site of the ADP protein to become exposed such that aggregation of further ADP, which may be native or heterologous to the system, to be promoted. The method can be carried out in vitro, or in cell- and animal-models, and may be used to screen for modulators of the aggregation process by monitoring aggregation e.g. by monitoring the production of the ADP-related degradation products resulting from the aggregation. Also provided are materials, processes for use in or with the methods.
摘要翻译：公开了诱导或模拟与通过诱导的构象聚合相互作用在ADP聚集物（例如阿尔茨海默病）的疾病状态相关的聚集性疾病蛋白（ADP-例如tau蛋白）的病理状态的方法，所述方法是其特征在于提供可膜可定位的融合蛋白的步骤，其包含（i）衍生自ADP的聚集部分或引发ADP的病理性聚集的蛋白质，（ii）异源膜定位部分。认为基于ADP的融合蛋白的膜定位导致ADP蛋白的高亲和力捕获位点被暴露，使得可以促进对系统天然或异源的另外的ADP的聚集。该方法可以在体外或细胞和动物模型中进行，并且可以用于通过监测聚集来筛选聚集过程的调节剂。通过监测由聚合产生的与ADP相关的降解产物的产生。还提供了用于或与该方法一起使用的材料，方法。

6. 发明申请

WO2007110627A3 3,7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USE 审中-公开
标题翻译： 3,7-二氨基-10H-苯并恶嗪盐及其用途
公开(公告)号：WO2007110627A3
公开(公告)日：2007-11-22
申请号：PCT/GB2007001103
申请日：2007-03-28
申请人： WISTA LAB LTD , WISCHIK CLAUDE MICHEL , RICKARD JANET ELIZABETH , HARRINGTON CHARLES ROBERT , HORSLEY DAVID , STOREY JOHN MERVYN DAVID , MARSHALL COLIN , SINCLAIR JAMES PETER , BADDELEY THOMAS CRAVEN
发明人： WISCHIK CLAUDE MICHEL , RICKARD JANET ELIZABETH , HARRINGTON CHARLES ROBERT , HORSLEY DAVID , STOREY JOHN MERVYN DAVID , MARSHALL COLIN , SINCLAIR JAMES PETER , BADDELEY THOMAS CRAVEN
IPC分类号： C07D279/20 , A61K31/5415 , A61P25/28
CPC分类号： A61K31/5415 , C07D279/20 , C07D279/22 , C09B21/00
摘要： This invention pertains generally to the field of phenothiazine compounds, and more particularly to certain stably reduced phenothiazine compounds, specifically, certain 3,7 diamino-10H-phenothiazine (DAPTZ) compounds of the following formula wherein: each of R 1 and R 9 is independently selected from: -H; C 1-4 alkyl; C 2-4 alkenyl; and halogenated C 1-4 alkyl; each of R 3NA and R 3NB is independently selected from: -H; C 1-4 alkyl; C 2-4 alkenyl; and halogenated C 1-4 alkyl; each of R 7NA and R 7NB is independently selected from: -H; C 1-4 alkyl; C 2-4 alkenyl; and halogenated C 1-4 alkyl; each of HX 1 and HX 2 is independently a protic acid; and pharmaceutically acceptable salts, solvates, and hydrates thereof. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease, and also as prodrugs for the corresponding oxidized thioninium drugs (for example, methythioninium chloride, MTC).
摘要翻译：本发明一般涉及吩噻嗪化合物领域，更具体地涉及某些稳定还原的吩噻嗪化合物，特别是下式的某些3,7-二氨基-10H-吩噻嗪（DAPTZ）化合物，其中：每个R 1，其中R 9和R 9独立地选自：-H; ç_{1-4 烷基; ç_{2-4 烯基; 和卤代C 1-4烷基; R 3NA和R 3NB中的每一个独立地选自：-H; ç_{1-4 烷基; ç_{2-4 烯基; 和卤代C 1-4烷基; R 7NA和R 7NB中的每一个独立地选自：-H; ç_{1-4 烷基; ç_{2-4 烯基; 和卤代C 1-4烷基; HX 1和HX 2各自独立地为质子酸; 及其药学上可接受的盐，溶剂化物和水合物。这些化合物可用作药物，例如用于治疗tau蛋白病如阿尔茨海默氏病，以及还用作相应的氧化th drugs类药物（例如甲硫in氯化物，MTC）的前体药物。}}}}}}

7. 发明申请

WO2002075318A2 NEUROFIBRILLARY LABELS 审中-公开
标题翻译：神经元标签
公开(公告)号：WO2002075318A2
公开(公告)日：2002-09-26
申请号：PCT/GB2002/001318
申请日：2002-03-20
申请人： THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN , WISCHIK, Claude, Michel , HARRINGTON, Charles, Robert , RICKARD, Janet, Elizabeth , HORSLEY, David
发明人： WISCHIK, Claude, Michel , HARRINGTON, Charles, Robert , RICKARD, Janet, Elizabeth , HORSLEY, David
IPC分类号： G01N33/68
CPC分类号： C07D417/12 , C07D277/66 , C07D279/20 , G01N33/583 , G01N33/6896
摘要： Disclosed are methods for determining the stage of neurofibrillary degeneration associated with a tauopathy in a subject believed to suffer from the disease, which methods comprise the steps of: (i) introducing into the subject a ligand capable of labelling aggregated paired helical filament (PHF) tau protein, (ii) determining the presence and/or amount of ligand bound to extracellular aggregated PHF tau in the medial temporal lobe of the brain of the subject, (iii) correlating the result of the determination made in (ii) with the extent of neurofibrillary degeneration in the subject. The methods can be used for pre-mortem diagnosis and staging of tauopathies such as Alzheimer's Disease. Preferred ligands include sulphonated-benzothiazole-like compounds and diaminophenothiazines. Novel ligands (e.g. sulphonated-benzothiazole-like compounds) are also provided. The method may also include the use of "blocking ligands" to block competing binding sites. In other aspects the invention provides in vitro methods for identifying ligands capable of labeling aggregated PHF tau protein, the methods comprising the steps of: (i) providing a first agent suspected of being capable of labeling aggregated PHF tau protein, (ii) contacting (a) a tau protein or a derivative thereof containing the tau core fragment bound to a solid phase so as to expose a high affinity tau capture site, with (b) a liquid phase tau protein or derivative thereof capable of binding to the solid phase tau protein or derivative, and (c) said selected first agent and (d) a second agent known to be tau-tau binding inhibitor, (iii) selecting first agent which fully or partially relieves the inhibition of binding of the liquid phase tau protein or derivative of (b) to the solid phase tau protein or derivative of (a) by the inhibitor (d). Ligands may also be tested to confirm that they are not themselves inhibitors.
摘要翻译：公开了用于确定被认为患有疾病的受试者中与tau蛋白病相关的神经原纤维变性的阶段的方法，该方法包括以下步骤：（i）将能够标记聚集的成对螺旋丝（PHF）的配体引入受试者， tau蛋白，（ii）确定与受试者脑内侧颞叶中细胞外聚集的PHF tau结合的配体的存在和/或量，（iii）将（ii）中确定的测定结果与的神经原纤维变性。这些方法可用于妊娠前诊断和分期的阿尔茨海默病等tau蛋白病。优选的配体包括磺化苯并噻唑类化合物和二氨基吩噻嗪。还提供了新的配体（例如磺化的苯并噻唑类化合物）。该方法还可以包括使用“阻断配体”来阻止竞争结合位点。在其它方面，本发明提供了用于鉴定能够标记聚集的PHF tau蛋白的配体的体外方法，所述方法包括以下步骤：（i）提供疑似能够标记聚集的PHF tau蛋白的第一药剂，（ii） a）包含与固相结合的tau核心片段的tau蛋白或其衍生物，以暴露高亲和力tau捕获位点，（b）能够结合固相tau的液相tau蛋白或其衍生物蛋白质或衍生物，和（c）所述选择的第一试剂和（d）已知为tau-tau结合抑制剂的第二药剂，（iii）选择完全或部分缓解液相tau蛋白结合抑制的第一药剂，或（b）衍生物与固相tau蛋白或（a）的抑制剂（d）的衍生物。也可以测试配体以确认它们本身不是抑制剂。

8. 发明申请

WO2002055720A3 MATERIALS AND METHODS RELATING TO PROTEIN AGGREGATION IN NEURODEGENERATIVE DISEASE 审中-公开
公开(公告)号：WO2002055720A3
公开(公告)日：2002-07-18
申请号：PCT/GB2002/000153
申请日：2002-01-15
申请人： THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN , WISCHIK, Claude, Michel , HORSLEY, David , RICKARD, Janet, Elizabeth , HARRINGTON, Charles, Robert
发明人： WISCHIK, Claude, Michel , HORSLEY, David , RICKARD, Janet, Elizabeth , HARRINGTON, Charles, Robert
IPC分类号： C12N15/85
摘要： Disclosed are methods of proteolytically converting a precursor protein (e.g. tau) to a product fragment (e.g. a 12 kd fragment) in a stable cell line, wherein the precursor protein is associated with a disease state in which the precursor protein aggregates pathologically (e.g. a tauopathy), and the methods comprise:(a) providing a stable cell line transfected with nucleic acid encoding: (i) a template fragment of the precursor protein such that the template fragment is constitutively expressed in the cell at a level which is not toxic to the cell; and (ii) the precursor protein, which protein is inducibly expressed in the cell in response to a stimulus, whereby interaction of the template fragment with the precursor protein causes a conformational change in the precursor protein such as to cause aggregation and proteolytic processing of the precursor protein to the product fragment. The method is preferably used to screen for modulators of the aggregation process by monitoring production (or modulation of production) of the product band or bands. Also provided are materials for used in the assays, plus medicaments, and related uses and processes, based on compounds which show high activity in the assay of the invention e.g. reduced diaminophenothiazines.

9. 发明申请

WO2010067078A3 3,6-DISUBSTITUTED XANTHYLIUM SALTS AS MEDICAMENTS 审中-公开
标题翻译： 3,6-取代的XANTHYLIUM SALTS作为药物
公开(公告)号：WO2010067078A3
公开(公告)日：2010-11-18
申请号：PCT/GB2009002865
申请日：2009-12-10
申请人： WISTA LAB LTD , CLUNAS SCOTT , STOREY JOHN MERVYN DAVID , RICKARD JANET ELIZABETH , HORSLEY DAVID , HARRINGTON CHARLES ROBERT , WISCHIK CLAUDE MICHEL
发明人： CLUNAS SCOTT , STOREY JOHN MERVYN DAVID , RICKARD JANET ELIZABETH , HORSLEY DAVID , HARRINGTON CHARLES ROBERT , WISCHIK CLAUDE MICHEL
IPC分类号： C07D491/22 , A61K31/352 , A61K31/382 , A61K31/4375 , A61K31/498 , A61K31/538 , A61P25/28 , C07D241/46 , C07D265/38 , C07D311/82 , C07D311/90 , C07D335/12 , C07D493/16
CPC分类号： C07D311/82 , A61K9/0053 , A61K31/352 , A61K31/382 , A61K31/4025 , A61K31/4545 , A61K31/4745 , A61K31/498 , A61K31/5377 , A61K31/538 , A61K45/06 , A61K49/00 , C07D241/46 , C07D265/38 , C07D311/84 , C07D311/90 , C07D335/12 , C07D335/14 , C07D335/20 , C07D491/16 , C07D491/22 , C07D493/16 , C09B11/24 , C09B11/28 , C09B17/00 , C09B19/00 , C09B21/00 , C09B57/00 , G01N33/6896 , G01N2800/7047
摘要： This invention pertains generally to processes, uses, methods and materials utilising particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease.
摘要翻译：本发明一般涉及使用特定的呫吨化合物（包括式（I）和（II）的化合物）的方法，用途，方法和材料，如本文进一步定义。这些化合物可用作药物，例如用于治疗tau蛋白病如阿尔茨海默氏病。

10. 发明申请

WO2010067078A8 3,6-DISUBSTITUTED XANTHYLIUM SALTS 审中-公开
标题翻译： 3,6-取代的XANTHYLIUM SALTS
公开(公告)号：WO2010067078A8
公开(公告)日：2010-09-02
申请号：PCT/GB2009002865
申请日：2009-12-10
申请人： WISTA LAB LTD , CLUNAS SCOTT , STOREY JOHN MERVYN DAVID , RICKARD JANET ELIZABETH , HORSLEY DAVID , HARRINGTON CHARLES ROBERT , WISCHIK CLAUDE MICHEL
发明人： CLUNAS SCOTT , STOREY JOHN MERVYN DAVID , RICKARD JANET ELIZABETH , HORSLEY DAVID , HARRINGTON CHARLES ROBERT , WISCHIK CLAUDE MICHEL
IPC分类号： C07D491/22 , C07D241/46 , C07D265/38 , C07D311/82 , C07D311/90 , C07D335/12
CPC分类号： C07D311/82 , A61K9/0053 , A61K31/352 , A61K31/382 , A61K31/4025 , A61K31/4545 , A61K31/4745 , A61K31/498 , A61K31/5377 , A61K31/538 , A61K45/06 , A61K49/00 , C07D241/46 , C07D265/38 , C07D311/84 , C07D311/90 , C07D335/12 , C07D335/14 , C07D335/20 , C07D491/16 , C07D491/22 , C07D493/16 , C09B11/24 , C09B11/28 , C09B17/00 , C09B19/00 , C09B21/00 , C09B57/00 , G01N33/6896 , G01N2800/7047
摘要： This invention pertains generally to processes, uses, methods and materials utilising particular xanthylium compounds, including compounds of formula (I) and (II), as further defined herein. These compounds are useful as drugs, for example, in the treatment of tauopathies, such as Alzheimer's disease.
摘要翻译：本发明一般涉及使用特定的呫吨化合物（包括式（I）和（II）的化合物）的方法，用途，方法和材料，如本文进一步定义。这些化合物可用作药物，例如用于治疗tau蛋白病如阿尔茨海默氏病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式